CD274 and lung carcinoma: Likewise, current clinical research pays more attention to bi-specific and tri-specific antibodies development as well as combination therapy, e.g. using anti-PD-L1 together with anti-TIGIT antibodies for lung cancer patients (NCT04294810) in order to obtain, on the one hand, better efficacy, on the other hand, to solve treatment resistance problems (41, 42).